PKCβ inhibitor 1?

Research use only, not for human use.

PKCβ inhibitor 1(KUN79359) is a potent selective and ATP-competitive inhibitor of PKC isozymes(IC50s of 21 and 5 nM for human PKCβ1 and PKCβ2 respectively).

PKCβ inhibitor 1(KUN79359) is a potent selective and ATP-competitive inhibitor of PKC isozymes(IC50s of 21 and 5 nM for human PKCβ1 and PKCβ2 respectively).

PKCβ inhibitor 1 (0-30 μM; 48 hours) suppresses tumor cell proliferation in a time- and dose-dependent manner.PKCβ inhibitor 1 (14 μM; 2-48 hours) induces apoptosis in 2F7 cells.PKCβ inhibitor 1 (15 μM; 2-48 hours) inhibits cell cycle progression in 2F7 and BCBL-1 cells.PKCβ (15 or 14 μM, respectively; 2-48 hours) inhibitor 1 reduces the expression of phospho-PKCβ in BCBL-1 and 2F7 cells.PKCβ inhibitor 1(0-48 hours) suppresses GSK3β, mTOR, and S6 phosphorylation. Cell Proliferation Assay Cell Line:2F7, BCBL-1 cells Concentration:0, 5, 10, 20, and 30 μMIncubation Time:48 hours Result:A dose-dependent reduction in viability of the 2F7 and BCBL-1 cells starting at 5 μM and increasing with elevated inhibitor concentration. Apoptosis Analysis Cell Line:2F7 cells Concentration:14 μM Incubation Time:2-48 hours Result:Apoptotic induction in 2.1% of the 2F7 cells above background after 2 hours of treatment, increasing through 48 hours of treatment.Cell Cycle AnalysisCell Line:BCBL-1 Cells Concentration:15 μM (the IC50)Incubation Time:2-48 hours Result:Inhibits cell cycle progression in 2F7 and BCBL-1 cells.Western Blot Analysis Cell Line:BCBL-1 and 2F7 cell lines Concentration:15 or 14 μM (at the IC50 respectively)Incubation Time:2-48 hours Result:The expression of phospho-PKCβ in BCBL-1 and 2F7 cells reduced.

——

KUN79359

Angiogenesis

PKC

PKCβ

——

——

257879-35-9

411.5

C24H21N5O2?

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (607.59 mM)

——

3-[1-(3-Imidazol-1-yl-propyl)-1H-indol-3-yl]-4-phenylamino-pyrrole-25-dione

(-20℃)

With Ice Pack

≥ 2 years